Welcome to our dedicated page for Johnson & Johnson SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Johnson & Johnson filed a Form 13F reporting institutional holdings on behalf of its investment manager. The report lists 20 holdings with a total reported market value of $503,699,862. The filing names Johnson & Johnson Innovation - JJDC, Inc. as an included manager and is signed on 11-13-2025.
Johnson & Johnson filed a Form 4 reporting open‑market sales of CVRx (CVRX) common stock by its subsidiary, Johnson & Johnson Innovation – JJDC, Inc. The filing lists sales of 52,332 shares at a weighted average price of $10.21 on 11/06/2025 and 200 shares at $10.00 on 11/07/2025. After these transactions, J&J indirectly beneficially owned 4,050,898 CVRx shares through JJDC. Prices for the 11/06 trades ranged from $10.00 to $10.49 per share.
Johnson & Johnson reported significantly stronger results for the quarter and first nine months of 2025. Quarterly sales rose to $23.99 billion, up 6.8% from a year ago, with net earnings climbing to $5.15 billion versus $2.69 billion. Diluted EPS increased to $2.12 from $1.11.
For the first nine months, sales reached $69.63 billion, up 5.0%, while net earnings more than doubled to $21.69 billion, and diluted EPS rose to $8.94 from $4.38. Results benefited from a roughly $7 billion reversal of previously accrued talc reserves, partly offset by a higher effective tax rate of 21.5% following U.S. tax law changes.
The company closed the $14.5 billion acquisition of Intra-Cellular Therapies, adding CAPLYTA and a CNS pipeline to the Innovative Medicine segment. MedTech growth was supported by prior acquisitions such as Shockwave. As of October 17, 2025, there were 2,409,295,102 common shares outstanding.
Johnson & Johnson (JNJ) insider trade: EVP, Innovative Medicine, R&D, John C. Reed exercised 21,721 employee stock options at $157.92 per share and sold 21,721 common shares at a weighted average price of $192.7072 on 10/17/2025. Following these transactions, he directly beneficially owned 10,658 common shares and held 43,442 derivative securities (options). The sale price reflects multiple trades between $192.69 and $192.87.
Johnson & Johnson (JNJ) filed a Form 144 notice covering a proposed sale of 21,721 shares of common stock with an aggregate market value of $4,185,794.26. The filing lists an approximate sale date of 10/17/2025 on the NYSE through Fidelity Brokerage Services LLC.
The securities were acquired on 10/17/2025 via an option granted on 02/15/2024, with payment made on 10/17/2025 in cash. The notice states 2,408,338,872 shares outstanding. Over the past three months, John C. Reed sold 19,137 shares on 07/17/2025 for gross proceeds of $3,129,830.51.
Johnson & Johnson filed an 8-K announcing two updates. First, it issued a press release reporting sales and earnings for the third quarter ended September 28, 2025. Second, it announced its intent to separate the Company’s Orthopaedics business.
The filing notes the related exhibits: Exhibit 99.1 contains the Q3 2025 press release and Exhibit 99.2 provides unaudited comparative supplementary sales data and a condensed consolidated statement of earnings for the fiscal third quarter and nine months. Exhibit 99.3 contains the press release about the planned Orthopaedics separation. These disclosures were dated October 14, 2025.
Johnson & Johnson filed an 8-K announcing two updates. First, it issued a press release reporting sales and earnings for the third quarter ended September 28, 2025. Second, it announced its intent to separate the Company’s Orthopaedics business.
The filing notes the related exhibits: Exhibit 99.1 contains the Q3 2025 press release and Exhibit 99.2 provides unaudited comparative supplementary sales data and a condensed consolidated statement of earnings for the fiscal third quarter and nine months. Exhibit 99.3 contains the press release about the planned Orthopaedics separation. These disclosures were dated October 14, 2025.
Johnson & Johnson filed an 8-K announcing two updates. First, it issued a press release reporting sales and earnings for the third quarter ended September 28, 2025. Second, it announced its intent to separate the Company’s Orthopaedics business.
The filing notes the related exhibits: Exhibit 99.1 contains the Q3 2025 press release and Exhibit 99.2 provides unaudited comparative supplementary sales data and a condensed consolidated statement of earnings for the fiscal third quarter and nine months. Exhibit 99.3 contains the press release about the planned Orthopaedics separation. These disclosures were dated October 14, 2025.
John G. Morikis submitted an initial Form 3 disclosing beneficial ownership in Johnson & Johnson (JNJ). The filing reports direct ownership of 598.51 shares and indicates Mr. Morikis serves as a director of the issuer. The event requiring the statement is dated 09/08/2025 and the Form 3 was signed by an attorney-in-fact on 09/15/2025. The filing is an initial ownership disclosure under Section 16.
John G. Morikis submitted an initial Form 3 disclosing beneficial ownership in Johnson & Johnson (JNJ). The filing reports direct ownership of 598.51 shares and indicates Mr. Morikis serves as a director of the issuer. The event requiring the statement is dated 09/08/2025 and the Form 3 was signed by an attorney-in-fact on 09/15/2025. The filing is an initial ownership disclosure under Section 16.
Marillyn A. Hewson, a director of Johnson & Johnson (JNJ), acquired 280.788 Deferred Share Units (DSUs) on 09/09/2025 under the company's Amended and Restated Deferred Fee Plan for Directors. The DSUs were recorded at a per-unit value of $178.07 and will be settled in cash upon termination of the reporter's directorship. The reported DSUs include accrued dividend equivalent rights tied to the issuer's quarterly dividend. Following the transaction the reporting person’s total DSU exposure is shown as 13,816.8727 units.
Daniel E. Pinto, a director of Johnson & Johnson (JNJ), acquired 175.493 Deferred Share Units (DSUs) on 09/09/2025 under the company's Amended and Restated Deferred Fee Plan for Directors. Each DSU equals the fair market value of one share of JNJ common stock at the business day before settlement and will be settled in cash when Mr. Pinto's directorship ends. The reported per-unit price for the DSUs is $178.07, resulting in 175.493 units held directly after the transaction. The Form 4 was filed and signed on 09/11/2025.
Johnson & Johnson director Eugene A. Woods reported an acquisition of 210.591 Deferred Share Units (DSUs) on 09/09/2025. The filing lists an acquisition price of $178.07 per unit and shows the reporting person beneficially owned 4,841.3962 DSUs following the transaction. The DSUs were granted under the issuer's Amended and Restated Deferred Fee Plan for Directors and were received in deferral of a cash retainer. The DSUs are payable in cash upon termination of the director's service and each DSU represents the fair market value of one share at settlement. The filing was signed by an attorney-in-fact on behalf of Mr. Woods on 09/11/2025.